Alginate-based sustained release drug delivery systems for tuberculosis

Bibliography

• Dye C, Watt CJ, Bleed DM, et al. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005;293:2767-75
   PubMed Web of Science ®Google Scholar
• Williams BG, Granich R, Chauhan LS, et al. The impact of HIV/AIDS on the control of tuberculosis in Indi. Proc Natl Acad Sci USA 2005;102:9619-24
   PubMed Web of Science ®Google Scholar
• Fine PEM. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995;346:1339-45
   PubMed Web of Science ®Google Scholar
• Chaisson RE, Martinson NA. ‘Tuberculosis in Africa – combating an HIV-driven crisis’ N Engl J Med 2008;358:1089-92
   PubMed Web of Science ®Google Scholar
• Xing Z. The Hunt for New Tuberculosis Vaccines: Anti-TB Immunity and Rational Design of Vaccines. Curr Pharm Des 2001;7:1015-37
   PubMed Web of Science ®Google Scholar
• Kirby DJ, Rosenkrands I, Agger EM, et al. PLGA microspheres for the delivery of a novel subunit TB vaccine. J Drug Target 2008;16:282-93
   PubMed Web of Science ®Google Scholar
• Zhu BD, Qie YQ, Wang JL, et al. Chitosan microspheres enhance the immunogenicity of an A985B-based fusion protein containing multiple T-cell epitopes of Mycobacterium tuberculosis. Eur J Pharm Biopharm 2007;66:318-26
   PubMed Web of Science ®Google Scholar
• Dobakhti F, Rahimi F, Dehpour AR, et al. Stabilizing effects of calcium alginate microspheres on Mycobac-terium bovis BCG intended for oral vaccination. J Microencapsul 2006;23:844-54
   PubMed Web of Science ®Google Scholar
• Ajdary S, Dobakhti F, Taghikhani M, et al. Oral administration of BCG encapsulated in alginate microspheres induces strong Th1 response in BALB/c mice. Vaccine 2007;25:4595-601
   PubMed Web of Science ®Google Scholar
• Kirby DJ, Rosenkrands I, Agger EM, et al. Liposomes act as stronger sub-unit vaccine adjuvants when compared to microspheres. J Drug Target 2008;16:543-54
   PubMed Web of Science ®Google Scholar
• du Toit LC, Pillay V, Danckwerts MP. Tuberculosis chemotherapy: current drug delivery approaches. Respir Res 2006;7:118
   PubMed Web of Science ®Google Scholar
• Jain KK. Delivery systems – an overview. Methods Mol Biol 2008;437:1-50
   PubMedGoogle Scholar
• Amar HO, Khalil RM. Preparation and evaluation of sustained release solid dispersions of drugs with Eudragit polymers. Drug Dev Ind Pharm 1997; 23:1043-54
   Web of Science ®Google Scholar
• Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004;21(5):387-422
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Polymer based drug delivery systems for mycobacterial infections. Curr Drug Del 2004;1:195-201
   PubMedGoogle Scholar
• Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004;23:243-55
   PubMed Web of Science ®Google Scholar
• Schatz A, Bugie B, Waksman S. Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc Soc Exp Biol Med 1944;55:65-9
   Google Scholar
• World Health Organization. Global tuberculosis control: surveillance, planning financing. WHO/HTM/TB/2005. WHO Report 2005; Geneva, Switzerland
   Google Scholar
• Chopra P, Meena LS, Singh Y. New drug targets for Mycobacterium. tuberculosis. J Med Res 2003;117:1-9
   Web of Science ®Google Scholar
• Christine MJ, Pandey R, Sharma S, et al. Oral therapy using nanoparticle encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium. Tuberculosis. Antimicrob Agents Chemother 2005;49:4335-8
   PubMed Web of Science ®Google Scholar
• Giovanni DP, Bonora S. Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis? J Antimicrob Chemother 2004;54:593-602
   PubMed Web of Science ®Google Scholar
• Zhang Y. The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 2005;45: 529-64
   PubMed Web of Science ®Google Scholar
• Falk R, Randolph TW, Meyer JD, et al. Controlled release of ionic compounds from poly (L-lactide) microspheres produced by precipitation with a compressed antisolvent. J Contr Rel 1997:441:77-85
   Google Scholar
• You JO, Park SB, Park HY, et al. Preparation of regular sized Ca-alginate microspheres using membrane emulsification method. J Microencapsul 2001;18:521-32
   PubMed Web of Science ®Google Scholar
• Smidsrod O, Draget KI. Chemistry and physical properties of alginates. Carbohydr Eur 1996;14:6-13
   Google Scholar
• Skjak-Braek G, Espevik T. Application of alginate gels in biotechnology and biomedicine. Carbohydr Eur 1996;14:19-25
   Web of Science ®Google Scholar
• Takka S, Acarturk F. Calcium alginate microparticles for oral administration: I. effect of sodium alginate type on drug release and drug entrapment efficiency. J Microencapsul 1999;16:275-90
   PubMed Web of Science ®Google Scholar
• Rajaonarivony M, Vauthier C, Couarraze G, et al. Development of a new drug carrier made from alginate. J Pharm Sci 1993;82:912-17
   PubMed Web of Science ®Google Scholar
• Ostberg T, Vesterhus L, Graffner C. Calcium alginate matrices for oral multiple unit administration: II. Effect of process and formulation factors on matrix properties. Int J Pharm 1993;97:183-93
   Web of Science ®Google Scholar
• Tonnesen HH, Karlsen J. Alginate in drug delivery systems. Drug Dev Ind Pharm 2002;28:621-30
   PubMed Web of Science ®Google Scholar
• Wong TY, Preston LA, Schiller NL. Alginate lyase: review of major sources and enzyme characteristics, structure–function analysis, biological roles, and applications. Annu Rev Microbiol 2000;54:289-340
   PubMed Web of Science ®Google Scholar
• Matricardi P, Meo CD, Coviello T, Alhaique F. Recent advances and perspectives on coated alginate microspheres for modified drug delivery. Expert Opin Drug Deliv 2008;5(4):417-25
   PubMed Web of Science ®Google Scholar
• Raj NK, Sharma CP. Oral insulin – a perspective. J Biomater Appl 2003;17:183-96
   PubMed Web of Science ®Google Scholar
• Joseph I, Venkataram S. Indomethacin sustained release from alginate–gelatin or pectin-gelatin coacervates. Int J Pharm 1995;126:161-8
   Web of Science ®Google Scholar
• Gonzalez-Rodriguez ML, Holgado MA, et al. Alginate–chitosan particulate systems for sodium diclofenac release. Int J Pharm 2002;232:225-34
   PubMed Web of Science ®Google Scholar
• Chickering III DE, Jacob JS, Desai TA, et al. Bioadhesive microspheres: III. An in vivo transit and bioavailability study of drug loaded alginate and poly (fumaric-co-sebacic anhydride) microspheres. J Control Release 1997;48:35-46
   Web of Science ®Google Scholar
• Iannuccelli V, Coppi G, Cameroni R. Biodegradable intraoperative system for bone infection treatment. I. The drug/polymer interaction. Int J Pharm 1996;143:195-201
   Google Scholar
• Cui JH, Goh JS, Park SY, et al. Preparation and physical characterization of alginate microparticles using air atomization method. Drug Dev Ind Pharm 2001;27:309-19
   PubMed Web of Science ®Google Scholar
• Whitehead L, Collett JH, Fell JT. Amoxycillin release from a floating dosage form based on alginates. Int J Pharm 2000;210:45-49
   PubMed Web of Science ®Google Scholar
• Lucinda-Silva RM, Evangelista RC. Microspheres of alginate–chitosan containing isoniazid. J Microencapsul 2003;20:145-52
   PubMed Web of Science ®Google Scholar
• Ain Q, Sharma S, Khuller GK, et al. Alginate based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother 2003;51:931-8
   PubMed Web of Science ®Google Scholar
• Ciofani G, Raffa V, Menciassi A, et al. A drug delivery system based on alginate microspheres: mass-transport test and in vitro validation. Biomed Microdevices 2007;9(3):395-403
   PubMed Web of Science ®Google Scholar
• Samad A, Sultana Y, Khar RK, et al. Radiolabeling and evaluation of alginate blend-isoniazid microspheres by Tc-99m for the treatment of tuberculosis in rabbit model. J Drug Target 2008;16:509-15
   PubMed Web of Science ®Google Scholar
• Takka S, Ocak OH, Acarturk F. Formulation and investigation of nicardiine HCl-alginate gel beads with factorial design-based studies. Eur J Pharm Sci 1998;6:241-6
   PubMed Web of Science ®Google Scholar
• Pandey R, Khuller GK. Chemotherapeutic potential of alginate chitosan microspheres as antitubercular drug carriers. J Anitimicrob Chemother 2004;53:635-40
   PubMed Web of Science ®Google Scholar
• Berrada M, Serreqi A, Dabbarh F, et al. A novel non-toxic camptothecin formulation for cancer chemotherapy. Biomaterials 2005;26:2115-20
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Pandey R, Sharma S, et al. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses. Int J Antimicrob Agents 2006;27:420-27
   Google Scholar
• Ahmad Z, Pandey R, Sharma S, et al. Alginate nanoparticles as antitubercular drug carriers: formulation development, pharmacokinetics and therapeutic potential. Indian J Chest Dis Allied Sci 2006;48:171-6
   PubMedGoogle Scholar
• Ahmad Z, Pandey R, Sharma S, et al. Evaluation of antitubercular drug loaded alginate nanoparticles against experimental tuberculosis. Nanoscience 2005;1:81-5
   Google Scholar
• Ahmad Z, Sharma S, Khuller GK. Inhalable Alginate Nanoparticles as Antitubercular Drug Carriers against Experimental Tuberculosis. Int J Antimicrob Agents 2005;26:298-303
   PubMed Web of Science ®Google Scholar
• Guardiola-Diaz HM, Foster LA, Mushrush D, et al. Azole–antifungal binding to a novel cytochrome P450 from Mycobacterium. tuberculosis. Biochem Pharmacol 2001;61:1463-70
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. In vitro and ex vivo antimycobacterial potential of azole drugs against M. tuberculosis. H37RV. FEMS Microbiol Lett 2005;251:19-22
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 2006;261:181-86
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett 2006;258:200-3
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK, et al. In vitro antimycobacterial potential of Econazole against multidrug resistant strains of Mycobacterium. tuberculosis. Int J Antimicrob Agents 2006;28(6):543-4
   PubMed Web of Science ®Google Scholar
• Pandey R, Ahmad Z, Sharma S, et al. Nano-encapsulation of azole antifungals: potential applications to improve oral drug bioavailability. Int J Pharm 2005;301:268-76
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis. Nanomedicine 2007;3:239-43
   PubMed Web of Science ®Google Scholar